Get the exact medicine name

Name the product

Get the medicine’s full name and find out which form is offered: a tablet, an injection or something else. Write that down separately from any name the clinic gives its treatment plan.

Peptides are short chains linking together the building blocks that proteins use.

The word peptide alone reveals nothing about a product’s U.S. approval as a medicine, as of September 26, 2026.

Ask what approval covers

Medicine reviews at the Food and Drug Administration (FDA) address specific uses.

For semaglutide (Ozempic) tablets and injections, the U.S. approval in place on September 26, 2026 was for helping adults manage blood sugar in type 2 diabetes alongside diet and exercise.

U.S. approval for semaglutide (Wegovy) tablets and injections covers losing weight and maintaining that loss, with changes to diet and activity, as of September 26, 2026.

Approval covers the named product for its specified use; a clinic’s entire treatment menu does not gain that approval.

BPC-157 has no U.S. drug approval as of September 26, 2026.

Whether a pharmacy may prepare a medicine to order depends on separate ingredient rules; its lack of approval alone leaves that question open.

Based on the FDA records checked September 26, 2026, BPC-157 does not meet the ingredient rules for a pharmacy making medicine for an individual patient.

Understand a made-to-order medicine

To compound a medicine, a pharmacist or doctor makes it for an order instead of supplying a finished factory product.

Compounded medicines reach sale without FDA approval or a prior FDA review, as of September 26, 2026.

The FDA makes no check of these medicines’ safety, quality or effectiveness before they go on sale.

The FDA says compounding can meet a patient need when an approved medicine cannot, or is not commercially available.

As of September 26, 2026, pharmacies making medicines for named patients cannot regularly make copies of medicines already supplied as finished products.

A change can qualify for an exception when the prescriber decides it makes a significant difference to the individual patient.

For instance, leaving out a dye that causes an allergy for the patient can address a need the factory-made medicine cannot meet.

A lower price alone does not meet the exception for a patient-specific change, as of September 26, 2026.

Read past the badge

Ask what the record behind a badge actually tells you.

FDA registration records a business with the Food and Drug Administration, and a drug listing puts information about its product on file.

Neither record establishes FDA approval or a legal right to sell the product under the U.S. rules checked September 26, 2026.

A National Drug Code (NDC), an identifying code in a drug directory, does not establish approval either.

A label saying “research use only” says the product is for laboratory work, not for treating people.

FDA letters on record as of September 26, 2026 accused sellers of illegally offering unapproved medicines for human use despite the research labels.

Those letters are accusations by the FDA about particular sellers, rather than decisions made by a court.

If someone offers a research-labeled product as your treatment, ask them to explain what allows it to be supplied for patient care; the label does not answer that question.